Diagnosis of pcos is now largely based on the Rotterdam criteria, which



Download 18.24 Kb.
Date20.07.2018
Size18.24 Kb.
PCOS

Diagnosis of PCOS is now largely based on the Rotterdam criteria, which

require two of three key features of oligo- or anovulation, clinical and/or biochemical hyperandrogenism and polycystic ovaries on ultrasound.
Calculated bioavailable testosterone, calculated free testosterone or free androgen index should be first line investigation for hyperandrogenism in polycystic ovary syndrome. If androgen levels are markedly above laboratory reference ranges, secondary causes may be considered. Late-onset congenital adrenal hyperplasia, although rare, needs to be considered.
It is difficult to assess androgen status in women on the OCP as effects include oestrogen mediated increases in sex hormone-binding globulin and reduction in androgens. Where the OCP has already been commenced, it should be withdrawn for at least three months before testing.
In adolescent women (<18 years), after two years of irregular cycles (>35 or < 21 days) following the onset of menarche, polycystic ovary syndrome should be considered as well as other causes of irregular cycles (eg thyroid dysfunction or hyperprolactinemia)
Treatment Options
Oligo menorrhoea/amenorrhoea


  • Lifestyle change (5%–10% weight loss + structured exercise)

  • Oral contraceptive pill (OCP) (low oestrogen doses [eg, 20μg] may have less impact on insulin resistance)

  • Cyclic progestins (eg, 10mg medroxyprogesterone acetate 10–14 days every 2–3 months)

  • Metformin (improves ovulation and regularity of periods)


Hirsutism

  • Eflornithine cream

  • OCP (monitor glucose tolerance in those at risk of diabetes)

  • Anti-androgen monotherapy (eg, spironolactone or cyproterone acetate) should not be used without adequate contraception

Trial therapies for 6 months before changing dose or medication

Combination therapy — if 6 months of OCP is ineffective, add anti-androgen to OCP (twice daily spironolactone > 50mg or cyproterone acetate 25mg/day, days 1–10 of OCP)

Self-administered and professional cosmetic therapy are also an option (laser recommended)
Infertility

• Lifestyle intervention (to optimise preconception health and fertility and reduce pregnancy and long-term complications)

• Advise on folate, smoking cessation and optimal weight and exercise before conception

• Infertility therapies may include clomiphene citrate, metformin, gonadotrophins, surgery and in-vitro fertilisation.


Cardio metabolic risk

• Lifestyle change: > 5% weight loss in those who are overweight reduces diabetes risk by approximately 50%–60% in high-risk groups

• Optimise cardiovascular risk factors- consider age, weight, BMI, waist circumference, smoking, lipid profile, BP, HBA1c

• Consider metformin (reduces the risk of diabetes by 50% in high risk groups


Lifestyle management, including diet and exercise programs, should be used throughout the life span in women with polycystic ovary syndrome to optimise

health generally and to alleviate polycystic ovary syndrome clinical severity including infertility, for weight loss, prevention of weight gain &



Pharmacological ovulation induction should not be recommended for first line therapy in women with polycystic ovary syndrome who are morbidly obese (body mass index _35 kg/m2) until appropriate weight loss has occurred either through diet, exercise, bariatric surgery, or other appropriate means.


Share with your friends:


The database is protected by copyright ©dentisty.org 2019
send message

    Main page